Van ECK Associates Corp Sells 1,648 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Van ECK Associates Corp lessened its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 30.1% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,836 shares of the company’s stock after selling 1,648 shares during the quarter. Van ECK Associates Corp’s holdings in Hims & Hers Health were worth $71,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC boosted its position in shares of Hims & Hers Health by 679.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after acquiring an additional 1,603 shares during the period. Quest Partners LLC boosted its position in shares of Hims & Hers Health by 5,944.1% in the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after acquiring an additional 3,507 shares during the period. CWM LLC boosted its position in shares of Hims & Hers Health by 21.4% in the third quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after acquiring an additional 1,054 shares during the period. Amalgamated Bank boosted its position in shares of Hims & Hers Health by 55.9% in the second quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after acquiring an additional 2,354 shares during the period. Finally, Daiwa Securities Group Inc. bought a new position in shares of Hims & Hers Health in the second quarter valued at approximately $142,000. Institutional investors own 63.52% of the company’s stock.

Wall Street Analyst Weigh In

HIMS has been the subject of a number of analyst reports. Needham & Company LLC initiated coverage on shares of Hims & Hers Health in a research report on Thursday, August 22nd. They issued a “buy” rating and a $24.00 price objective for the company. Truist Financial raised their price objective on shares of Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a research report on Thursday, July 18th. TD Cowen raised their target price on shares of Hims & Hers Health from $25.00 to $28.00 and gave the company a “buy” rating in a research note on Friday, November 8th. Deutsche Bank Aktiengesellschaft raised their target price on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research note on Wednesday, November 6th. Finally, Imperial Capital downgraded shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Eight equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $21.21.

Insider Transactions at Hims & Hers Health

In other news, CEO Andrew Dudum sold 188,888 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $14.56, for a total value of $2,750,209.28. Following the transaction, the chief executive officer now owns 33,502 shares in the company, valued at approximately $487,789.12. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Christiane Pendarvis sold 7,000 shares of Hims & Hers Health stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $15.15, for a total value of $106,050.00. Following the sale, the director now owns 23,917 shares in the company, valued at $362,342.55. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Andrew Dudum sold 188,888 shares of Hims & Hers Health stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the completion of the sale, the chief executive officer now owns 33,502 shares in the company, valued at approximately $487,789.12. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 854,547 shares of company stock worth $15,987,230. Insiders own 17.71% of the company’s stock.

Hims & Hers Health Stock Performance

HIMS stock opened at $27.60 on Thursday. The company has a market capitalization of $5.93 billion, a PE ratio of 62.73 and a beta of 1.06. Hims & Hers Health, Inc. has a one year low of $7.18 and a one year high of $30.44. The company’s 50 day moving average price is $19.25 and its two-hundred day moving average price is $18.70.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $401.56 million for the quarter, compared to analysts’ expectations of $382.20 million. During the same quarter last year, the business earned ($0.04) earnings per share. The business’s revenue was up 77.1% on a year-over-year basis. On average, research analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.